AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SLN · NASDAQ · Biotechnology

Silence Therapeutics (ADR)

Develops liver-targeted siRNA medicines through its mRNAi GOLD platform.

$13.42

After-hours close−0.04 (−0.30%)

At close$13.46(+0.07%)

Something off on this page? Send us feedback.

Profile

Silence Therapeutics plcSLNHealth Care

Develops liver-targeted siRNA medicines through its mRNAi GOLD platform. As a clinical-stage biotechnology company, it advances programs for polycythemia vera, high lipoprotein(a), and dyslipidemia while using external collaboration in discovery.

Develops siRNA medicines through the mRNAi GOLD platform, which uses RNA interference to target disease-associated genes without permanently altering DNA. Its GalNAc linkage is designed to direct siRNAs to liver cells, making liver-targeted discovery the core of its operating model. It also supports liver-focused partnered discovery with external collaborators.

The clinical pipeline includes divesiran for polycythemia vera, zerlasiran for high lipoprotein(a), and SLN312 for dyslipidemia. The company also uses external collaboration in discovery and alliance management. Its Nasdaq-listed ADSs are its only publicly tradable securities after the AIM admission was cancelled.

Company facts

CEOIain Ross

ListedSep 8, 2020

ExchangeNASDAQ

HeadquartersLondon, United Kingdom

CountryUnited Kingdom

Employees88

CIK0001479615

ISINUS82686Q1013

Key statistics

Market cap$633.9M

EPS (ttm)−$3.33

P/E (ttm)−4.03

ROE-106.9%

P/B5.49

P/S1,031.89

Dividend yield—

Beta1.50vs XLV 0.54

Year to date +119% · Average volume (30d) 1.5M

Analysts

Price target, next 12 months$55.00+309.8%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy4 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $13.42

High$67.00+399.3%

Median$55.00+309.8%

Low$49.00+265.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating
Jun 24, 2026	Cantor Fitzgerald	Initiate	Overweight

Earnings

EPS

Estimate−$0.12

ReportedDue Nov 5, 2026

Revenue

Estimate$124.2K

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	−$0.13	−$0.26	−104.4%	$1.1M	$137.2K	−87.9%	+29.12%
May 7, 2026Q1 FY26	−$0.33	−$0.32	+3.0%	$1.3M	$422.0K	−66.4%	+0.29%
Mar 5, 2026Q4 FY25	−$0.32	−$0.25	+21.9%	$2.9M	$39.0K	−98.7%	+13.27%
Nov 6, 2025Q3 FY25	−$0.40	−$0.45	−12.5%	$3.1M	$159.0K	−94.9%	+2.02%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$183.7K	$307.2K	$159.0K	$34.0K	$421.3K	$0
Gross profit	$113.8K	$190.6K	$95.0K	$22.0K	$304.5K	−$108.2K
Operating income	−$36.8M	−$32.9M	−$26.2M	−$12.5M	−$15.0M	−$13.1M
Net income	−$36.9M	−$37.5M	−$21.0M	−$11.8M	−$14.9M	−$12.3M
Diluted EPS	−$2.34	−$2.40	−$1.32	−$0.27	−$0.96	−$0.78
Gross margin	62.0%	62.1%	59.7%	64.7%	72.3%	—
Operating margin	-20,006.4%	-10,697.8%	-16,505.7%	-36,650.0%	-3,565.4%	—

Fiscal years (4-quarter sums)FY21 $12.4M · FY22 $17.5M · FY23 $25.4M · FY24 $41.8M · FY25 $683.9K

Revenue by product · Q4 FY25

Research Collaboration Income$235.0K · 100%

Revenue by geography · FY24

Germany$144.0K · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $72.1M · Total debt $112.0K · Total assets $106.4M · Shareholders' equity $38.5M

Dividends

No dividends on record.

Ownership

Institutions 42.15%Insiders —

Shares outstanding 47.23M · Float 37.67M · 79.8% free float

Insiders — filings are in the shares behind the receipt.

A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.

This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Richard Ian Griffiths	34.54M	24.40%	13D	Jun 25, 2025
Richard Griffiths	14.39M	7.97%	13D	Aug 13, 2026
TCG Crossover Management, LLC	3.03M	6.42%	13F	May 15, 2026
Siren, L.L.C.	2.91M	6.16%	13F	May 14, 2026
Redmile Group, LLC	2.16M	4.58%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 10, 2026	Richard Ian Griffiths	10 percent owner	−5,484,320	$16.00
Jul 6, 2026	Richard Ian Griffiths	10 percent owner	−865,112	$10.53
Jul 2, 2026	Richard Ian Griffiths	10 percent owner	−50,082	$10.47
Jul 1, 2026	Richard Ian Griffiths	10 percent owner	−129,180	$10.62
Jun 30, 2026	Richard Ian Griffiths	10 percent owner	−169,928	$10.76